Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
J Pediatr ; 259: 113487, 2023 08.
Article in English | MEDLINE | ID: mdl-37201683

ABSTRACT

OBJECTIVE: To analyze laboratory testing results from pediatric patients newly diagnosed with celiac disease to determine the usefulness of each test derived from recommended guidelines. METHODS: Serological testing at the time of diagnosis from patients enrolled in our celiac disease registry from January 2018 through December 2021 was reviewed. The incidence of abnormal laboratory results, routinely obtained as per the recommendations of Snyder et al and our institution's Celiac Care Index, was assessed. Rates of abnormal laboratory values and estimated costs associated with these screening measures were analyzed. RESULTS: Our data demonstrated abnormalities in all serological testing obtained at celiac diagnosis. Hemoglobin, alanine aminotransferase, ferritin, iron, and vitamin D screening were found to be abnormal with notable frequency. Only 7% of patients had an abnormal thyroid-stimulating hormone and <0.1% had an abnormal free T4. Nonresponse to hepatitis B vaccination was prominent, with 69% of patients considered nonimmune. Screening protocols as currently outlined in our Celiac Care Index resulted in an estimated cost of approximately $320 000 during our study. CONCLUSIONS: Review of screening laboratory results at our center reveals that abnormal values for several recommended measures are uncommon. Thyroid screening was infrequently abnormal and the usefulness of screening for hepatitis B at diagnosis is uncertain. Similarly, our data suggest that iron deficiency screening may be condensed effectively into hemoglobin and ferritin testing, eliminating the need for initial iron studies. Decreasing baseline screening measures could safely decrease the burden of testing on patients and overall healthcare expenditures.


Subject(s)
Celiac Disease , Humans , Child , Celiac Disease/diagnosis , Celiac Disease/epidemiology , Celiac Disease/complications , Iron , Mass Screening , Ferritins , Hemoglobins
2.
Pediatr Rev ; 42(10): 529-538, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34599052
3.
J Pediatr ; 224: 158-161.e2, 2020 09.
Article in English | MEDLINE | ID: mdl-32593411

ABSTRACT

Current screening guidelines in North America for celiac disease recommend additional IgG based testing for younger children. Our multicenter retrospective study showed that the anti-tissue transglutaminase IgA antibody test should be the recommended initial test in all children, including those ≤24 months of age.


Subject(s)
Celiac Disease/blood , GTP-Binding Proteins/blood , Transglutaminases/blood , Biomarkers/blood , Case-Control Studies , Celiac Disease/diagnosis , Female , Humans , IgA Deficiency/blood , Immunoglobulin A/blood , Infant , Male , Protein Glutamine gamma Glutamyltransferase 2 , Retrospective Studies
4.
J Pediatr ; 216: 32-36.e2, 2020 01.
Article in English | MEDLINE | ID: mdl-31706635

ABSTRACT

OBJECTIVES: To describe quality improvement efforts to reduce variability in the care of children diagnosed with celiac disease through use of an institutional patient registry and a chronic care index. STUDY DESIGN: An institutional patient registry tracked rates of follow-up visits and repeat serologic testing. A Celiac Care Index that included anthropometrics, biopsy expectations, dietician consultation, and baseline laboratory evaluation was developed to standardize evaluation at diagnosis. Provider education sessions communicated expectations for this standard of care and order sets within the electronic medical record simplified test collection. Data was recorded and reviewed weekly and structured communications with providers were provided biweekly. RESULTS: Adherence with follow-up expectations (77%-89% P = .03) and repeat serologic testing (50%-90% P < .0001) significantly increased during the study period. Adherence with completion of the Celiac Care Index resulted in significant improvement in obtaining complete blood count (80%-98% P < .0001), iron (25%-78% P < .0001), ferritin (34%-80% P < .0001), alanine aminotransferase/aspartate aminotransferase (74%-96% P < .0001), thyroid-stimulating hormone (64%-90% P < .0001), vitamin D (36%-83% P < .0001), and hepatitis B immune status (30%-80% P < .0001). Iron deficiency demonstrated by low ferritin levels was common (41%) and a high rate of nonimmunity to hepatitis B (70%) was detected. CONCLUSIONS: The Celiac Care Index improved adherence with published care recommendations and reduced variability in baseline evaluation at diagnosis. Laboratory test results indicate further studies are needed to evaluate these recommendations.


Subject(s)
Celiac Disease/therapy , Quality Improvement , Registries , Celiac Disease/blood , Child , Humans , Patient Compliance/statistics & numerical data , Prospective Studies
5.
J Pediatr Gastroenterol Nutr ; 69(6): 690-695, 2019 12.
Article in English | MEDLINE | ID: mdl-31436704

ABSTRACT

OBJECTIVES: Celiac disease (CD) is a common chronic condition with potential adverse physical and psychosocial implications for affected children. The study purpose was to characterize health-related quality of life (HRQOL) in a large sample of pediatric patients with newly diagnosed CD using the PedsQL 4.0 Generic Core Scales, and compare it to that of healthy children and children with nonceliac gastrointestinal (GI) conditions using historic data. METHODS: The PedsQL was administered to 159 children with newly diagnosed CD and their parents at either the time of diagnostic esophagogastroduodenoscopy or before their initial dietitian appointment for gluten-free diet teaching. Mean parent-report and self-report PedsQL summary and subscale scores were calculated, then compared to published means from a sample of healthy children and a sample of children with nonceliac GI symptoms using 1-sample t tests. RESULTS: Compared to the healthy children, those with newly diagnosed CD had lower Total Scores, Physical Health, Psychosocial Health, Emotional Functioning, and School Functioning on parent report (P < 0.008) with similar findings on self-report. Within the CD sample, clinically significant scores were found in 55.9% for School Functioning, 62.7% for Physical Health, 54.4% for Emotional Functioning, 43.7% for Social Functioning, and 49% for Total Score. CONCLUSIONS: Children and adolescents with newly diagnosed CD had lower HRQOL than healthy children and similar HRQOL to that of patients with nonceliac GI conditions. Patients with deficits in domains such as school or emotional functioning may benefit from early interventions including a Section 504 plan or meeting with a psychologist or social worker.


Subject(s)
Celiac Disease/psychology , Quality of Life , Surveys and Questionnaires/standards , Case-Control Studies , Celiac Disease/physiopathology , Child , Female , Humans , Male , Parents
6.
Stem Cell Reports ; 10(1): 17-26, 2018 01 09.
Article in English | MEDLINE | ID: mdl-29276155

ABSTRACT

The intestinal epithelium serves as an essential barrier to the outside world and is maintained by functionally distinct populations of rapidly cycling intestinal stem cells (CBC ISCs) and slowly cycling, reserve ISCs (r-ISCs). Because disruptions in the epithelial barrier can result from pathological activation of the immune system, we sought to investigate the impact of inflammation on ISC behavior during the regenerative response. In a murine model of αCD3 antibody-induced small-intestinal inflammation, r-ISCs proved highly resistant to injury, while CBC ISCs underwent apoptosis. Moreover, r-ISCs were induced to proliferate and functionally contribute to intestinal regeneration. Further analysis revealed that the inflammatory cytokines interferon gamma and tumor necrosis factor alpha led to r-ISC activation in enteroid culture, which could be blocked by the JAK/STAT inhibitor, tofacitinib. These results highlight an important role for r-ISCs in response to acute intestinal inflammation and show that JAK/STAT-1 signaling is required for the r-ISC regenerative response.


Subject(s)
Enteritis/metabolism , Intestinal Mucosa/physiology , Intestine, Small/metabolism , Janus Kinases/metabolism , Regeneration , STAT1 Transcription Factor/metabolism , Signal Transduction , Stem Cells/metabolism , Acute Disease , Animals , Apoptosis/drug effects , Cytokines/metabolism , Enteritis/chemically induced , Enteritis/pathology , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/pathology , Intestinal Mucosa/pathology , Intestine, Small/pathology , Janus Kinases/antagonists & inhibitors , Mice , Mice, Transgenic , Piperidines/pharmacology , Pyrimidines/pharmacology , Pyrroles/pharmacology , STAT1 Transcription Factor/antagonists & inhibitors , Stem Cells/pathology
7.
J Pediatr Gastroenterol Nutr ; 63(3): 340-3, 2016 09.
Article in English | MEDLINE | ID: mdl-27548248

ABSTRACT

OBJECTIVES: The aim of the present study was to determine the proportion of pediatric patients with celiac disease (CD) who had transaminases obtained at diagnosis and to determine the proportion with hypertransaminasemia. METHODS: Data from newly diagnosed patients with CD at Nationwide Children's Hospital from February 2007 to March 2014 were retrospectively reviewed. Alanine transaminase (ALT) and aspartate transaminase (AST) values at diagnosis and after initiation of a gluten-free diet (GFD) were assessed. RESULTS: Of 388 patients (mean age 10.1 ±â€Š4.4 years, 235 girls), 185 (47.7%) had transaminases obtained at the time of diagnosis. Twenty-eight of one hundred eighty-five (15.1%) had an elevated ALT and/or AST level with an average ALT 2.52 × upper limit of normal (ULN) and AST 1.87 × ULN. Those with hypertransaminasemia were younger than those with normal levels (6.31 ±â€Š4.75 vs 11.00 ±â€Š4.28 years, P < 0.0001). Sex, symptoms at diagnosis, and weight, height, and body mass index z scores were not predictive of elevated transaminases. Of the 21 patients with hypertransaminasemia at diagnosis who had repeat laboratory test results after starting the GFD, 15 (71.4%) normalized whereas 6 (28.6%) remained elevated. CONCLUSIONS: There is variation in practice among pediatric gastroenterologists in the assessment of transaminases in children with CD. Hypertransaminasemia is present at diagnosis in a significant proportion of children with CD although at a lower frequency than previously reported. Younger patients are more likely to have an elevation in transaminases. Abnormal transaminases normalize in the majority of patients within 1 year after initiation of a GFD.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Celiac Disease/blood , Liver Diseases/diagnosis , Adolescent , Case-Control Studies , Celiac Disease/complications , Celiac Disease/pathology , Child , Female , Humans , Liver Diseases/blood , Liver Diseases/complications , Male , Retrospective Studies
8.
Pediatrics ; 138(3)2016 09.
Article in English | MEDLINE | ID: mdl-27565548
9.
J Pediatr Gastroenterol Nutr ; 61(4): 440-4, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25944219

ABSTRACT

OBJECTIVE: Histologic changes in celiac disease (CD) may be patchy or confined to the bulb. Present guidelines recommend obtaining multiple biopsies from the bulb and distal duodenum when evaluating for CD. Adherence to these recommendations among adult gastroenterologists is low. There are no such data for pediatric gastroenterologists. This study compared endoscopic biopsy practices among pediatric gastroenterologists in histologically confirmed patients with CD to those without histologically confirmed CD. METHODS: Retrospective review of esophagogastroduodenoscopies (EGDs) during a 13-month period was performed. Children with histologically confirmed CD and a random sample of age-matched children without CD were identified. Endoscopy and histology reports were reviewed. The site and number of biopsy samples obtained was recorded. The groups were compared for number of biopsies. RESULTS: A total of 98 children with CD were compared with 103 controls without CD. The number of biopsies obtained in the group with CD was higher than the group without CD (5.9 ±â€Š1.6 vs 3.6 ±â€Š1.2) (P < 0.0001). In children with CD, 80.5% had ≥5 biopsies compared with 11.7% in the group without CD (P < 0.0001). Only 10% of the children in the group with CD had bulb biopsies documented compared with none in the group without CD. CONCLUSIONS: Pediatric gastroenterologists at our center generally obtain the recommended number of biopsies in children with histologically confirmed CD but seldom document biopsies from the bulb. In those without histologic evidence of CD, fewer biopsies are obtained with none documented from the bulb. Failure to take the recommended number of biopsies could result in some missed cases of CD.


Subject(s)
Celiac Disease/diagnosis , Duodenum/pathology , Endoscopy, Gastrointestinal/adverse effects , Guideline Adherence , Intestinal Mucosa/pathology , Pediatrics/methods , Adolescent , Biopsy , Celiac Disease/pathology , Child , Child, Preschool , Cohort Studies , Diagnosis, Differential , Endoscopy, Gastrointestinal/standards , European Union , Female , Hospitals, Pediatric , Humans , Male , Ohio , Pediatrics/standards , Practice Guidelines as Topic , Retrospective Studies , Societies, Medical , United States , Workforce
10.
Pediatr Rev ; 35(10): 409-15; quiz 416, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25274968

ABSTRACT

On the basis of strong evidence, gastrointestinal symptoms and failure to thrive are classic presentations of celiac disease, but atypical, nongastrointestinal symptoms are also extremely common, particularly in the older child and adolescent. (3)(4)(8). On the basis of some research evidence and consensus, guidelines recommend celiac testing in symptomatic children with typical and atypical symptoms and consideration of testing in those with associated conditions and first-degree relatives of those with celiac disease. (3)(9). On the basis of strong research evidence, measurement of tTG IgA and total serum IgA level has been reported to be the most cost-effective and accurate means of serologic testing for celiac disease and is the test of choice unless the child is younger than 2 years or IgA deficient. (9). On the basis of strong research evidence, children with elevated titers of celiac antibodies or strong clinical suspicion for celiac disease should be referred to a gastroenterologist for upper endoscopy and biopsy. Until this procedure is performed, the child should continue on a diet with ingestion of gluten. (3)(9). On the basis of strong research evidence, all those with a confirmed diagnosis of celiac disease should follow a strict gluten-free diet for life, with avoidance of all foods that contain wheat, barley, and rye ingredients. (3)(4). Referral to a health care professional with specialized knowledge of celiac disease and the gluten-free diet is critical because of the numerous ways, often hidden, in which gluten may be present in the diet and environment.


Subject(s)
Celiac Disease/diagnosis , Antibodies/analysis , Biopsy , Celiac Disease/diet therapy , Child , Diet, Gluten-Free , Endoscopy, Gastrointestinal , Humans , Intestines/pathology
11.
Invest Ophthalmol Vis Sci ; 43(7): 2450-61, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12091450

ABSTRACT

PURPOSE: Lysophosphatidic acid (LPA) is a phospholipid growth factor that stimulates proliferation, chemotaxis, cation currents, and K(+) currents in retinal pigment epithelial (RPE) cells. LPA receptor transduction was analyzed in human and rat RPE cells. METHODS: Cells were cultured with standard methods, and signaling pathways were analyzed with a variety of approaches, including whole-cell recording, calcium imaging, and second-messenger assays. RESULTS: LPA-activated nonselective cation currents in rat RPE were blocked by the protein tyrosine kinase (PTK) inhibitor genistein, by the MAP kinase kinase (MEK) inhibitor PD98059, and by loading cells with antibodies to G(alpha(i)/o/t/z). LPA activated the MAP kinase and extracellular signal-related kinase (ERK)-1, and produced a dose-dependent inhibition of cAMP production. LPA stimulated a dose-dependent increase in [Ca(2+)](i) that persisted in Ca(2+)-free medium and was reduced by pretreatment with thapsigargin, suggesting it involves release from intracellular stores. The [Ca(2+)](i) increase was not blocked by ryanodine or the phospholipase C inhibitor U73122. LPA did not stimulate inositol phosphate production. Similar to the cation current, LPA-evoked [Ca(2+)](i) increases were blocked by PD98059 and by loading cells with antibodies to G(alpha(i)/o/t/z). RT-PCR experiments showed the presence of RNA for three LPA receptor subtypes (Edg2, -4, and -7); RNase protection assays showed the strongest expression for Edg2 receptor RNA. CONCLUSIONS: LPA receptors in RPE cells activate pertussis toxin (PTx)-sensitive G proteins that inhibit cAMP accumulation; stimulate MAP kinase which activates a cation current and probably contributes to mitogenesis; and stimulate release of Ca(2+) from intracellular stores that appears independent of IP(3) and ryanodine receptor activation.


Subject(s)
Pigment Epithelium of Eye/metabolism , Receptors, Cell Surface/metabolism , Receptors, G-Protein-Coupled , Signal Transduction , Animals , Blotting, Western , Calcium/metabolism , Cells, Cultured , Cyclic AMP/antagonists & inhibitors , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Humans , Lysophospholipids/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Patch-Clamp Techniques , Pigment Epithelium of Eye/drug effects , Rats , Rats, Long-Evans , Receptors, Lysophosphatidic Acid , Reverse Transcriptase Polymerase Chain Reaction , Second Messenger Systems/physiology
12.
Mol Endocrinol ; 16(8): 1828-39, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12145337

ABSTRACT

The Na+/H+ exchanger regulatory factor (NHE-RF; also known as ezrin-radixin-moesin binding protein 50) is a primary response gene under estrogen receptor (ER) control that may provide a link between estrogen action and the regulation of cytoskeletal and cell-signaling pathways. These studies were undertaken to define the human NHE-RF genomic regions and regulatory sequences mediating its robust estrogen responsiveness. Screening of a human genomic library yielded NHE-RF clones comprising the full gene, including the 5'-regulatory region and first exon, which were found to contain a large number (13) of consensus half-estrogen response elements (EREs), but to lack palindromic full EREs. Transfection-transactivation assays with wild-type and mutant ERs and reporter gene constructs linked to progressive deletions, or containing mutations, of the 5'-flanking region including a portion of exon I, and electrophoretic mobility and competitive gel shift assays were performed. These demonstrated direct ER interaction with the multiple half-ERE sites and the importance of the one proximal half-ERE and the multiple upstream half-EREs for eliciting the robust transcription activation of the NHE-RF gene by the estrogen-ER complex. Our findings highlight a paradigm for gene regulation via numerous half-ERE sites that expands the range of modes by which DNA recognition sites mediate the actions of this nuclear receptor.


Subject(s)
Carrier Proteins/genetics , Phosphoproteins/genetics , Receptors, Estrogen/metabolism , Amino Acid Sequence , Base Sequence , Binding Sites/genetics , Cell Line , DNA, Complementary/genetics , DNA, Complementary/metabolism , Exons , Genes, Regulator , Humans , In Vitro Techniques , Molecular Sequence Data , Promoter Regions, Genetic , Sodium-Hydrogen Exchangers/metabolism , Sp1 Transcription Factor/metabolism
13.
Biochim Biophys Acta ; 1582(1-3): 240-50, 2002 May 23.
Article in English | MEDLINE | ID: mdl-12069834

ABSTRACT

Lysophosphatidic acid (LPA) is a bioactive lipid mediator and important component of serum. Studies over the past several years which have documented diverse effects of LPA on multiple types of airway cells and which suggest possible involvement of LPA in lung disease are reviewed here. LPA enhances contractility of airway smooth muscle. It also stimulates proliferation of cultured airway smooth muscle cells and exhibits a striking synergism with epidermal growth factor (EGF) for stimulating mitogenesis. Recent studies of the molecular components and signaling pathways mediating synergism are described, including LPA-induced upregulation of EGF receptors and activation of multiple transcription factors by both LPA and EGF. A model for the effects of LPA and EGF on mitogenesis that includes EGF receptor upregulation and synergism between Ras and Rho for activation of the transcription factor AP-1 is presented. LPA stimulates fibronectin secretion and filopodia extension in airway epithelial cells as well as proliferation and collagen gel contraction by lung fibroblasts. A hypothesis for LPA involvement in the airway repair and remodeling, which contribute to the pathology of asthma and other airway diseases, is presented, and future directions for research into the roles of LPA in airway function and disease are suggested.


Subject(s)
Lysophospholipids/physiology , Respiratory Physiological Phenomena , Respiratory Tract Diseases/physiopathology , Signal Transduction/physiology , Animals , Asthma/physiopathology , Cell Division , Epidermal Growth Factor/physiology , Humans , MAP Kinase Signaling System/physiology , Respiratory Mucosa/physiology , Respiratory Tract Diseases/pathology
14.
Am J Physiol Lung Cell Mol Physiol ; 282(1): L91-8, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11741820

ABSTRACT

Human airway smooth muscle cells treated with lysophosphatidic acid (LPA) and epidermal growth factor (EGF) exhibit synergistic stimulation of mitogenesis (Ediger TL and Toews ML. J Pharmacol Exp Ther 294: 1076-1082, 2000). The effects of LPA treatment of human airway smooth muscle cells on EGF receptor (EGFR) regulation have now been investigated. LPA treatment for 12-24 h resulted in a twofold increase in (125)I-EGF binding and EGFR protein levels as assessed by Western blot analysis. Competition binding assays indicated single-site binding with an affinity of 3 nM, and the affinity was not changed by LPA treatment. EGFR upregulation was blocked by cycloheximide and actinomycin D, suggesting that LPA influences transcriptional regulation of EGFR expression. Inhibitor studies revealed a prominent role for activation of mitogen-activated protein kinase and p70 ribosomal S6 kinase. Both synergism and EGFR upregulation increased with increased cell density, whereas EGFR expression in control cells decreased. The similar requirements for exposure time, LPA concentrations, and cell confluence suggest that EGFR upregulation may be one contributing factor to the synergistic stimulation of mitogenesis seen with LPA plus EGF.


Subject(s)
ErbB Receptors/metabolism , Lysophospholipids/pharmacology , Muscle, Smooth/metabolism , Trachea/metabolism , Binding, Competitive , Cells, Cultured , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Drug Synergism , Epidermal Growth Factor/pharmacology , Humans , Mitogens/pharmacology , Mitosis , Muscle, Smooth/cytology , Nucleic Acid Synthesis Inhibitors/pharmacology , Protein Synthesis Inhibitors/pharmacology , Protein-Tyrosine Kinases/metabolism , Signal Transduction/drug effects , Time Factors , Trachea/cytology , Up-Regulation , Virulence Factors, Bordetella/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...